Table IV-ETime to Event Outcomes

StudyTime to Event Outcomes
Gasparini et al. 2007
Im et al. 2005OutcomeGrpNMed (mos)1 yr2 yr3 yr4 yr5 yrTestpHR (95%CI)
TTPsHER2+42.8LR<0.001
sHER2-198.3
RDsHER2+31.50LR<0.001
sHER2-136.7~43~33
OSsHER2+412.4~50~26LR0.076
sHER2-23not reached~72~56
Fornier et al. 2005
Muller et al. 2004OutcomeGrpNMed (mos)1 yr2 yr3 yr4 yr5 yrTestpHR (95%CI)Comments
OSsHER2+/EC19~8.4~50~15~0LR0.092
sHER2-/EC35~22~77~40~15
sHER2+/ET18~16~60~10~0LRNS
sHER2-/ET29~14~65~10~0
PFSsHER2-/EC35~7~30~0~0LRNS
sHER2-/ET29~9~21~0~0
sHER2+/EC19~12~21~0~0LR0.0341
sHER2+/ET18~9~28~0~0
Luftner et al. 2004OutcomeGrpNMn (mos)1 yr2 yr3 yr4 yr5 yrTestpHR (95%CI)
Resp DursHER2+96.0~0LR0.042
sHER2-52~60
PFSsHER2+223~3LR0.098
sHER2-134~10
Sandri et al. 2004OutcomeGrpNMn (mos)1 yr2 yr3 yr4 yr5 yrTestpHR (95%CI)Comments
TTPsHER2+?2~0~0~0LR0.007
sHER2-?11~34~12~7
OSsHER2+?11~47~0~0LR<0.001
sHER2-?16~84~49~42
Colomer et al. 2004OutcomeGrpNMed (mos)1 yr2 yr3 yr4 yr5 yrTestpHR (95%CI)Comments
Resp DursHER2+57.9~40~0LR0.04
sHER2-2414.4~55~37
Burstein et al. 2003OutcomeGrpNMed (mos)1 yr2 yr3 yr4 yr5 yrTestpHR (95%CI)Comments
9520, Lipton et al. 2003OutcomeGrpNMed (mos)1 yr2 yr3 yr4 yr5 yrTestpHR (95%CI)Comments
TTPsHER2+164
letrazole876.1~28~7~6~4Cox0.05960.73 (0.53,1.01)
tamoxiven773.3~17~5~3
sHER2-398
letrazole19612.2~53~29~20~14Cox0.00190.70 (0.56,0.88)
tamoxiven2028.5~38~20~10~8
TTFsHER2+164
letrazole876.0Cox0.0418
tamoxiven773.2
sHER2-398
letrazole19611.6Cox0.0066
tamoxiven2026.2
11880, Esteva et al. 2002OutcomeGrpNMed (mos)1 yr2 yr3 yr4 yr5 yrTestpHR (95%CI)Comments
14870, Colomer et al. 2000OutcomeGrpNMed (mos)1 yr2 yr3 yr4 yr5 yrTestpHR (95%CI)Comments
Resp DursHER2+157.5~26LR0.035
sHER2-2411~50~35MV Cox0.06
22050, Colomer et al. 2006OutcomeGrpNMed (mos)1 yr2 yr3 yr4 yr5 yrTestpHR (95%CI)Comments
26670, Yamauchi et al. 1997OutcomeGrpNMed (mos)1 yr2 yr3 yr4 yr5 yrTestpHR (95%CI)Comments
TTPsHER2+32~3~13~13Cox0.00030.36 (0.21, 0.63) adjusted
sHER2-62~8~43~28
OSsHER2+32~28~74~54Cox0.0030.35 (0.17, 0.70) adjusted
sHER2-62~92~63

From: Appendix C. Evidence Data Abstraction Tables

Cover of HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors
HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors.
Evidence Reports/Technology Assessments, No. 172.
Seidenfeld J, Samson DJ, Rothenberg BM, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.